XL-Protein and Easton Pharmaceutical Sign License Agreement to Develop Biopharmaceuticals Using PASylation® Technology

by Business Wire • 2015/12/17 • 0 Comments

FREISING, Germany & CHENGDU, China--(BUSINESS WIRE)--XL-protein and Easton Pharmaceutical Sign License Agreement to Develop Biopharmaceuticals Using PASylation® Technology

← ALPHAEON completes acquisition of LENSAR

Roche files direct de novo application to FDA for Anti-Mullerian assay →

Post navigation